Wall Street is positive on Tandem Diabetes Care Inc (TNDM). On average, analysts give Tandem Diabetes Care Inc a Buy rating. The average price target is $119.4, which means analysts expect the stock to decline by -9.61% over the next twelve months. That average ranking earns Tandem Diabetes Care Inc an Analyst Rating of 15, which is better than 15% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating TNDM a Buy today. Find out what this means to you and get the rest of the rankings on TNDM!